Marcela Valverde-Monge, Patricia Sánchez-Carrasco, Diana Betancor, Blanca Barroso, José Manuel Rodrigo-Muñoz, Ignacio Mahillo-Fernández, Ebymar Arismendi, Irina Bobolea, Blanca Cárdaba, María Jesús Cruz, Victoria Del Pozo, Javier Domínguez-Ortega, Francisco Javier González-Barcala, José María Olaguibel, Juan Alberto Luna-Porta, Carlos Martínez-Rivera, Joaquim Mullol, Xavier Muñoz, Lorena Peleteiro-Pedraza, Cesar Picado Valles, Vicente Plaza, Santiago Quirce, Manuel Jorge Rial, Lorena Soto-Retes, Antonio Valero, Joaquín Sastre
BACKGROUND: Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission. OBJECTIVES: To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission...
January 2024: Archivos de Bronconeumología